Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, India Tindale, Elizabeth Greene et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 26
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsSimbarashe Takuva, Shelly Karuna, Michal Juraska et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 11
1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected IndividualsSrilatha Edupuganti, Lawrence Corey, Nyaradzo Mgodi et al.|Open Forum Infectious Diseases|2019Cited by 0
Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized TrialsSimbarashe Takuva, Nyaradzo Mgodi, Shelly Karuna et al.|SSRN Electronic Journal|2021Cited by 0
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsP. Andrew, John Hural, Larissa M. Villela et al.|UNC Libraries|2023Cited by 0